罕见病临床试验清单:FOR-DMD 试验的经验与障碍
FOR-DMD 是一项由 NIH 资助、旨在寻找杜氏肌营养不良最佳类固醇方案的学术主导国际多中心试验,原计划 40 个中心于 2011 年 7 月启动招募,实际至 2013 年 1 月才开始。文章梳理其从资助批准到中心启动的全流程,归纳延迟原因并提出预判与减少障碍的清单。
要点
- 跨国多中心启动时间 6 至 24 个月不等,延迟涉及药物供应、合同与监管差异。
- 学术主导试验缺乏合同研究组织的基础设施与专业支持,可加剧启动延迟。
- 作者提出清单作为 interim solution,用于预判并减少学术国际试验启动延迟。
核心结论
- 基于 FOR-DMD 经验制定清单,作为 interim solution 预判并减少学术国际试验启动延迟,并识别需多方利益相关者协同解决的障碍。
研究设计与样本
- 以 FOR-DMD 学术主导国际多中心临床试验为案例,梳理从资助批准到中心启动的完整时间线,系统识别并分组启动期问题。
主要发现
- 各国从首次接触到中心启动的时间为 6 至 24 个月。
- 延迟原因包括通用因素(申办方协议、药物采购、预算限制)、国家特异因素(监管流程复杂多样、赔偿要求)与中心特异因素(合同与审批)。
- 主要障碍包括药物供应问题、NIH 对非美国中心合同的要求、五国监管要求差异、合同缺乏国家统一协调及研究材料语言多样。
临床怎么用
- 学术机构启动国际多中心试验前应参照清单预判药物供应、合同与各国监管差异等环节,提前安排资源与协商。
局限性
- 延迟影响了招募,并挑战研究结局的临床相关性,可能延误患者获得最佳治疗;原文未报告样本量与效应量等定量结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Trials in rare diseases have many challenges, among which are the need to set up multiple sites in different countries to achieve recruitment targets and the divergent landscape of clinical trial regulations in those countries. Over the past years, there have been initiatives to facilitate the process of international study set-up, but the fruits of these deliberations require time to be operationally in place. FOR-DMD (Finding the Optimum Steroid Regimen for Duchenne Muscular Dystrophy) is an academic-led clinical trial which aims to find the optimum steroid regimen for Duchenne muscular dystrophy, funded by the National Institutes of Health (NIH) for 5 years (July 2010 to June 2015), anticipating that all sites (40 across the USA, Canada, the UK, Germany and Italy) would be open to recruitment from July 2011. However, study start-up was significantly delayed and recruitment did not start until January 2013. METHOD: The FOR-DMD study is used as an example to identify systematic problems in the set-up of international, multi-centre clinical trials. The full timeline of the FOR-DMD study, from funding approval to site activation, was collated and reviewed. Systematic issues were identified and grouped into (1) study set-up, e.g. drug procurement; (2) country set-up, e.g. competent authority applications; and (3) site set-up, e.g. contracts, to identify the main causes of delay and suggest areas where anticipatory action could overcome these obstacles in future studies. RESULTS: Time from the first contact to site activation across countries ranged from 6 to 24 months. Reasons of delay were universal (sponsor agreement, drug procurement, budgetary constraints), country specific (complexity and diversity of regulatory processes, indemnity requirements) and site specific (contracting and approvals). The main identified obstacles included (1) issues related to drug supply, (2) NIH requirements regarding contracting with non-US sites, (3) differing regulatory requirements in the five participating countries, (4) lack of national harmonisation with contracting and the requirement to negotiate terms and contract individually with each site and (5) diversity of languages needed for study materials. Additionally, as with many academic-led studies, the FOR-DMD study did not have access to the infrastructure and expertise that a contracted research organisation could provide, organisations often employed in pharmaceutical-sponsored studies. This delay impacted recruitment, challenged the clinical relevance of the study outcomes and potentially delayed the delivery of the best treatment to patients. CONCLUSION: Based on the FOR-DMD experience, and as an interim solution, we have devised a checklist of steps to not only anticipate and minimise delays in academic international trial initiation but also identify obstacles that will require a concerted effort on the part of many stakeholders to mitigate.
引用
- Crow RA, Hart KA, McDermott MP, et al. A checklist for clinical trials in rare disease: obstacles and anticipatory actions-lessons learned from the FOR-DMD trial. Trials. 2018. PMID: 29793540. doi:10.1186/s13063-018-2645-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。